Exogenus Therapeutics – one of the hottest startups of 2017!

Exogenus was one of the 20 biotech startups selected to participate at Bio Europe 2017 Startup Slam taking place on November 7th in Berlin. Participants will have the chance to present in front of a jury of investors, dealmakers and biotech KOL’s. Check out Labiotech’s article on the event. Joana Correia said: “Bio Europe Startup Slam is Read more about Exogenus Therapeutics – one of the hottest startups of 2017![…]

Exogenus distinguished at Merck Venture Lounge

Exogenus was distinguished as one of the most innovative Life Sciences & Medtech projects in Europe at Merck Venture Lounge, 2017! The Venture Lounge is an initiative of EASME through SME Instrument Phase 3 services. https://ec.europa.eu/easme/en/news/pitching-contest-merck-venture-lounge-and-sme-instrument-starts-today Joana Correia on this award: “For a startup it’s really important to have the recognition of relevant industry players, special on Read more about Exogenus distinguished at Merck Venture Lounge[…]

Exogenus Therapeutics participates in Cord Blood World Europe 2017

Joana Correia, Executive Director and Chief Scientific Officer presented last week at Cord Blood World Europe. Under the theme: “Umbilical cord blood supply for the development of Exo-Wound, an exosome-based product for chronic wounds” Joana talked about the technology behind Exo-Wound and the advantages and challenges of using exosomes as a therapeutic tool but also about Read more about Exogenus Therapeutics participates in Cord Blood World Europe 2017[…]

Exogenus Therapeutics finalist at 2nd EWMA Wound Care Innovation Symposium

Exogenus Therapeutics was one of the three finalist projects of the EWMA Alira Health 2nd Wound Care Innovation Symposium that took place on May 4th, at the European Wound Management Association Conference in Amsterdam. Having the opportunity to present its innovative technology to industry leaders and clinicians during this recognized international forum was part of the Read more about Exogenus Therapeutics finalist at 2nd EWMA Wound Care Innovation Symposium[…]

Joana Simões Correia selected as a Young Transatlantic Innovation Leader 2017

It was announced last week that Joana Simões Correia, the Executive Director of Exogenus Therapeutics (Exo-T) is one of the Young Transatlantic Innovation Leaders of 2017. The Young Transatlantic Innovative Leaders Initiative Fellowship is the flagship program of the Young Transatlantic Innovation Leaders Initiative (YTILI) of the U.S. Department of State and is supported in Read more about Joana Simões Correia selected as a Young Transatlantic Innovation Leader 2017[…]

Exo-T is recruiting

EDITAL PARA A ATRIBUIÇÃO DE BOLSA Bolsa de Doutoramento (1) Encontra-se aberto concurso para a atribuição de uma Bolsa de Doutoramento no âmbito do projeto interno: “Desenvolvimento de um medicamento biológico para tratamento de feridas da pele” da Exogenus Therapeutics, nas seguintes condições: Área Científica: Engenharia Biomédica Requisitos de admissão: Serão admitidos a concurso os Read more about Exo-T is recruiting[…]

Exogenus Therapeutics winner of the Everis Foundation Award 2016

It was announced today that Exogenus Therapeutics (Exo-T) is the winner of the Everis Foundation Award 2016. The award, which every year distinguishes projects from Industry, Biotechnology & Health, and Digital Economy originating from countries where the Everis Group has operations, counted in this XV edition with more than 600 applications from 10 different countries. Read more about Exogenus Therapeutics winner of the Everis Foundation Award 2016[…]

Exogenus Therapeutics to receive support from Horizon 2020’s SME Instrument Phase 1

Exogenus Therapeutics (Exo-T) is one of the selected SMEs to receive support from the European Commission under the Horizon 2020’s SME Instrument Phase 1. With the SME Instrument, the European Commission aims to support high growth, highly innovative European SMEs with global ambitions and with a mission to disrupt existing markets. This is a highly Read more about Exogenus Therapeutics to receive support from Horizon 2020’s SME Instrument Phase 1[…]